Invitrogen™ Ongericimab Recombinant Monoclonal Antibody

Ongericimab, also known as a recombinant humanized anti-PCSK9 monoclonal antibody, is primarily used to treat hypercholesterolemia by reducing low-density lipoprotein cholesterol (LDL-C) levels. The PCSK9 gene, located on chromosome 1p32.3, spans 22 kilobases and consists of 12 exons and 11 introns. It encodes a 692 amino acid glycoprotein involved in lipid metabolism, comprising a signal peptide (amino acids 1-30), a prosegment or inhibitory prodomain (amino acids 31-152), a subtilisin-like catalytic domain (amino acids 153-452), and a cysteine-histidine-rich C-terminal domain. PCSK9 plays a pivotal role in cholesterol homeostasis by promoting the degradation of low-density lipoprotein receptors (LDLR) in the liver, thereby increasing plasma LDL levels. Mutations in PCSK9 can lead to disorders such as familial hypercholesterolemia. In addition to its well-established role in cardiovascular diseases, emerging research indicates that PCSK9 variants may influence cancer outcomes and that PCSK9 inhibition can enhance the efficacy of immune checkpoint therapies.